Hadean Ventures, an Oslo, Norway- and Stockholm, Sweden-based life science venture capital firm, closed Hadean Capital II, at EUR 144M.
LPs included existing investors as well as a number of new investors including EIF, KfW Capital and Tesi.
The fund will invest in life science startup companies across Europe with a focus on the Nordics and German-speaking countries. The strategy includes pharma, biotech, medtech, diagnostics and digital health.
Launched in September 2021 and led by Managing Partners Ingrid Teigland Akay, and Walter Stockinger, Hadean Capital II has invested in six companies including Alex Therapeutics, Arthex Biotech, Complement Therapeutics, Emergence Therapeutics, Ribbon Biolabs and TargED. The first exit was already achieved with the acquisition of Emergence Therapeutics by Eli Lilly.
Hadean Ventures is a life science fund manager with approx. EUR 230m assets under management.